set to go?

This looks like an interesting play to me. Expect positive news flow moving forward and media attention as they present at a number of industry conferences/seminar's over the next few months. IMV it justifies a valuation > current $6m mkt cap given they are testing 10-12 of the top drugs sold in the world to see if their platform delivers it in a more efficient manner than current administration techniques. Looking at some of the others working in the same space (PSD, ACR, POH Mkt cap: $260m, $96m and $58m respectively) could see rapid escalation in share price in my view.
Also, unlike drug companies, there technology is a device for administration so doesn't take anywhere near as long to do testing to gain approval.

I hold OBJ.

Do your own research but I think looks good.